IFG Advisory’s Catalyst Pharmaceutical CPRX Stock Holding History

IFG Advisory’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,795	Closed	-$93K	–	499
2021 Q4	$93K	Buy	13,795 +72	+0.5%	+$473	0.01%	490
2021 Q3	$72K	Hold	13,723	–	–	0.01%	477
2021 Q2	$78K	Buy	+13,723	New	+$70.8K	0.01%	469

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

IFG Advisory's CPRX Position: Q1 2022 in Review

IFG Advisory sold out of Catalyst Pharmaceutical (CPRX) in Q1 2022, closing a stake of 13,795 shares — an estimated $93K sold.

IFG Advisory first reported a position in CPRX in Q2 2021 and held it in 3 quarters. The position peaked at $93K in Q4 2021. 187 funds tracked by Wall St. Rank hold CPRX as of Q1 2022.

IFG Advisory reported no remaining Catalyst Pharmaceutical position as of Q1 2022 after selling out during the quarter.
IFG Advisory sold 13,795 Catalyst Pharmaceutical shares in Q1 2022, an estimated $93K.
IFG Advisory first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 3 quarters.
IFG Advisory's Catalyst Pharmaceutical position peaked at $93K in Q4 2021.
187 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2022.

Based on IFG Advisory's 13F filing for Q1 2022, filed 4 May 2022.